Brain STimulation for ANxiety and Depression in Youth
Launched by UNIVERSITY OF CALGARY · Mar 19, 2025
Trial Information
Current as of September 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Brain STimulation for ANxiety and Depression in Youth," is exploring whether a treatment called Transcranial Magnetic Stimulation (TMS) can help improve symptoms of anxiety and depression in children and teenagers. The trial will include young people aged 6 to 18 who have been diagnosed with anxiety or depression by a qualified doctor. However, there are certain conditions that may prevent some individuals from participating, such as a recent history of seizures, specific medical conditions, or if they are currently pregnant.
Participants in the study can expect to receive TMS treatment, which is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. The trial is currently not recruiting participants, but once it starts, it aims to gather important information on how effective TMS can be for managing anxiety and depression in young people. If you or someone you know is interested, it’s essential to discuss eligibility and any potential questions with a healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. aged between 6 and 18 years old
- • 2. diagnosis of anxiety or depression made by a qualified medical professional
- • 3. active anxiety and/or depression symptoms
- Exclusion Criteria:
- • 1. status epilepticus in past 12-months
- • 2. presence of any disease, medical condition, or physical condition that, in the opinion of the study investigator may compromise, interfere, limit, affect, or reduce the participant's ability to complete the study
- • 3. hospitalization for suicide attempt within the past 3 months
- • 4. TMS-related contraindications, including implanted medical devices (e.g., pacemaker)
- • 5. if actively taking prescription medication, no changes in medication for at least 3 months prior to entry into the study, with no anticipation of change in the frequency or dose over the duration of the study, unless changes to medication are required for participant safety
- • 6. unable to understand instructions in English
About University Of Calgary
The University of Calgary is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university's clinical research initiatives aim to address pressing health challenges and improve patient outcomes. The institution fosters a robust environment for academic inquiry, leveraging state-of-the-art facilities and a diverse network of experts in various fields. Committed to ethical research practices and community engagement, the University of Calgary strives to translate scientific discoveries into tangible benefits for society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Calgary, Alberta, Canada
Patients applied
Trial Officials
Kara Murias, MD/PhD
Principal Investigator
The University of Calgary
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported